Alexander S. Geha

Alexander S. Geha

Auto-generated profile, based on publicly available information

Alexander S. Geha

Division of Cardiothoracic Surgery, The University of Illinois Medical Center at Chicago, 840 S. Wood Street, CSB 417 (MC 958), Chicago, Illinois 60612, United States

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in Cardiology
Verified
Journal Article
Closed access
AGAlexander S. Geha
Alexander S. Geha
CEChawki El-Zein
Chawki El-Zein
MMMalek G. Massad
Malek G. Massad
Congestive heart failure (CHF) is a chronic, progressive disease and its central element is the remodeling of the cardiac chamber associated with ventricular dilatation. Secondary mitral regurgitation is a complication of end-stage cardiomyopathy and is associated with a poor prognosis. It is due to progressive mitral annular dilatation and alteration in the geometry of the left ventricle. A vicious cycle of continuing volume overload, ventricular dilatation, progression of annular dilatation, increased left ventricular wall tension and worsening mitral regurgitation and CHF occurs. The mainstays of medical therapy are diuretics and afterload reduction, which are associated with poor long-term survival in these patients. Historically, the surgical approach to patients with mitral regurgitation was mitral valve replacement, but these patients were not considered operative candidates because of their high morbidity and mortality. Heart transplantation is now considered standard treatment for select patients with end-stage heart disease; however, it is applicable only to a small number of patients. Mitral valve replacement in these patients is associated with adverse consequences on left ventricular systolic function resulting from interruption of the annulus-papillary muscle continuity. Preserving the mitral valve apparatus and left ventricle in mitral valve repair enhances and maintains left ventricular function and geometry with an associated decrease in wall stress. Using these operative techniques to alter the shape of the left ventricle, in combination with optimal medical management for heart failure, improves survival and may avoid or postpone transplantation.

1 November 2001 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
AGAlexander S. Geha
Alexander S. Geha
MMMalek G. Massad
Malek G. Massad
NSNorman J. Snow
Norman J. Snow

15 December 2007 in World Journal of Surgery
Verified
Journal Article
Closed access
AGAlexander S. Geha
Alexander S. Geha
KAKhaled Abdelhady
Khaled Abdelhady

1 November 2006 in Recent Patents on Cardiovascular Drug Discovery
Verified
Journal Article
Closed access
SDSapan Desai
Sapan Desai
MMMalek Massad
Malek Massad
RDRobert DiDomenico
Robert DiDomenico
KAKhaled Abdelhady
Khaled Abdelhady
ZHZiad Hanhan
Ziad Hanhan
AGAlexander Geha
Alexander Geha
Warfarin and heparin have formed the mainstay in the prophylaxis of deep vein thrombosis (DVT), stroke prevention in atrial fibrillation, and treatment of thromboembolic disease (TED). However, these choices are hampered by difficult administration, interactions with other medications, side effect profile, and limited indications for treatment. Anti-factor Xa (anti-Xa) inhibitors have already entered the drug market with the drug Fondaparinux being the first anti-Xa inhibitor to be approved for use in the U.S. by the Food and Drug Administration (FDA), and other drugs such as idraparinux being currently in development. A new class of medications, known as direct thrombin inhibitors (DTI), includes the parental agents lepirudin, argatroban and bivalirudin which have been approved by the FDA and the oral agents ximelagatran, melagatran and dabigatran. The latter three drugs which are oral DTIs may soon replace warfarin and heparin as the preferred medications for DVT prophylaxis and for reducing the relative risk of stroke. These drugs do not rely on blocking serine proteases nor do they require a co-factor (antithrombin III) like unfractionated heparin (UFH) or low molecular weight heparin (LMWH). DTIs are rapid in onset, easy to administer, do not interact with other medications or foods, have limited side effects, and can be administered in a fixed dose. The DTI ximelagatran has already been approved in several European and Asian countries, and over a dozen randomized clinical trials have been conducted demonstrating its performance to be on par with warfarin. However, approval by the FDA in the U.S. remains pending in view of reported incidences of elevations in hepatic enzymes that are currently under evaluation. This review examines the role of DTIs in the prevention and treatment of TED and the recent patents reported in the literature.